Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Telomir Pharmaceuticals, Inc. (TELO) had Income from Continuous Operations of $-10.41M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-10.41M |
|
-- |
|
-- |
|
$10.54M |
|
$-10.54M |
|
$0.13M |
|
$-10.41M |
|
$-10.41M |
|
$-10.41M |
|
|
Income from Continuous Operations |
$-10.41M |
$-10.41M |
|
$-10.41M |
|
$-10.54M |
|
$-10.54M |
|
31.65M |
|
31.65M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$7.34M |
|
-- |
|
-- |
|
$7.34M |
|
$1.43M |
|
-- |
|
-- |
|
$1.43M |
|
$5.91M |
|
$5.91M |
|
$5.91M |
|
34.38M |
|
| Cash Flow Statement Financials | |
$-3.69M |
|
-- |
|
$9.71M |
|
$1.27M |
|
$7.29M |
|
$6.02M |
|
$5.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.69M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-176.10% |
|
-176.10% |
|
-141.84% |
|
-176.10% |
|
$0.17 |
|
$-0.12 |
|
$-0.12 |
|